Fulcrum Therapeutics/FULC

$7.50

-3.96%
-
1D1W1MYTD1YMAX

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Ticker

FULC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alex Sapir

Employees

76

Headquarters

Cambridge, United States

FULC Metrics

BasicAdvanced
$464.51M
Market cap
-
P/E ratio
-$1.59
EPS
2.31
Beta
-
Dividend rate
$464.51M
2.31074
$13.70
$2.39
640.05K
17.711
-40.19%
-44.84%
-42.88%
165.602
1.974
1.975
-55.77%
36.11%
-31.75%

What the Analysts think about FULC

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
76.67% upside
High $19.00
Low $5.00
$7.50
Current price
$13.25
Average price target

FULC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,087.5% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$800K
14.29%
Net income
$-24.7M
2.92%
Profit margin
-3,087.5%
-9.95%

FULC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.04%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.41
-$0.38
-$0.39
-$0.40
-
Expected
-$0.46
-$0.44
-$0.44
-$0.43
-$0.44
Surprise
-9.99%
-14.52%
-10.34%
-6.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Fulcrum Therapeutics stock?

Fulcrum Therapeutics (FULC) has a market cap of $464.51M as of April 15, 2024.

What is the P/E ratio for Fulcrum Therapeutics stock?

The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of April 15, 2024.

Does Fulcrum Therapeutics stock pay dividends?

No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Fulcrum Therapeutics dividend payment date?

Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.

What is the beta indicator for Fulcrum Therapeutics?

Fulcrum Therapeutics (FULC) has a beta rating of 2.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Fulcrum Therapeutics stock price target?

The target price for Fulcrum Therapeutics (FULC) stock is $13.25, which is 76.67% above the current price of $7.5. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Fulcrum Therapeutics stock

Buy or sell Fulcrum Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing